878 related articles for article (PubMed ID: 29416544)
1. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
Front Immunol; 2018; 9():51. PubMed ID: 29416544
[TBL] [Abstract][Full Text] [Related]
2. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
[TBL] [Abstract][Full Text] [Related]
3. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.
Schure RM; Hendrikx LH; de Rond LG; Oztürk K; Sanders EA; Berbers GA; Buisman AM
Clin Vaccine Immunol; 2013 Sep; 20(9):1388-95. PubMed ID: 23825195
[TBL] [Abstract][Full Text] [Related]
4. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
[TBL] [Abstract][Full Text] [Related]
5. Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.
van der Lee S; van Rooijen DM; de Zeeuw-Brouwer ML; Bogaard MJM; van Gageldonk PGM; Marinovic AB; Sanders EAM; Berbers GAM; Buisman AM
Front Immunol; 2018; 9():681. PubMed ID: 29670634
[TBL] [Abstract][Full Text] [Related]
6. Identification of pertussis-specific effector memory T cells in preschool children.
de Rond L; Schure RM; Öztürk K; Berbers G; Sanders E; van Twillert I; Carollo M; Mascart F; Ausiello CM; van Els CA; Smits K; Buisman AM
Clin Vaccine Immunol; 2015 May; 22(5):561-9. PubMed ID: 25787136
[TBL] [Abstract][Full Text] [Related]
7. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
8. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.
Decker MD; Greenberg DP; Johnson DR; Pool V
Vaccine; 2019 Aug; 37(35):5003-5008. PubMed ID: 31301919
[TBL] [Abstract][Full Text] [Related]
10. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
11. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
12. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
13. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
[TBL] [Abstract][Full Text] [Related]
14. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
Pérez Chacón G; Estcourt MJ; Totterdell J; Marsh JA; Perrett KP; Campbell DE; Wood N; Gold M; Waddington CS; O' Sullivan M; McAlister S; Curtis N; Jones M; McIntyre PB; Holt PG; Richmond PC; Snelling T
PLoS Med; 2024 Jun; 21(6):e1004414. PubMed ID: 38857311
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
19. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
20. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
